Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel as First-Line Therapy for High-Risk LBCL
NCT06935136Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 2 years. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06935136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935136.